HOOKIPA Pharma Inc. (HOOK)
Stock Price:
$9.58 USD
-0.19 (-1.94%)
Updated Oct 19, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
245.77M |
| Revenue (ttm) |
16.04M |
| Net Income (ttm) |
-39.65M |
| Shares Out |
21.83M |
| EPS (ttm) |
-1.55 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 19, 2020 |
| Last Price |
$9.58 |
| Previous Close |
$9.77 |
| Change ($) |
-0.19 |
| Change (%) |
-1.94% |
| Day's Open |
10.01 |
| Day's Range |
9.53 - 10.01 |
| Day's Volume |
45,408 |
| 52-Week Range |
5.80 - 14.37 |
More Stats
| Market Cap |
245.77M |
| Enterprise Value |
162.97M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
21.83M |
| Float |
11.80M |
| EPS (basic) |
-1.43 |
| EPS (diluted) |
-1.55 |
| FCF / Share |
-1.51 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
873,950 |
| Short Ratio |
10.19 |
| Short % of Float |
7.41% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
15.33 |
| PB Ratio |
2.41 |
| Revenue |
16.04M |
| Operating Income |
-48.49M |
| Net Income |
-39.65M |
| Free Cash Flow |
-38.60M |
| Net Cash |
82.80M |
| Net Cash / Share |
3.23 |
| Gross Margin |
-214.32% |
| Operating Margin |
-302.34% |
| Profit Margin |
-247.20% |
| FCF Margin |
-240.69% |
| ROA |
-20.11% |
| ROE |
-33.05% |
| ROIC |
-141.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (4)
| Buy |
4 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$17.75*
(85.28% upside)
Low
15.0
Current: $9.58
High
20.0
Target: 17.75
*Average 12-month price target from 4 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | 11.94 | 7.63 | - |
| Revenue Growth | 56.53% | - | - |
| Gross Profit | 11.94 | 7.63 | - |
| Operating Income | -51.09 | -21.18 | -14.16 |
| Net Income | -43.04 | -16.24 | -12.72 |
| Shares Outstanding | 17.86 | 0.91 | 0.91 |
| Earnings Per Share | -2.41 | -17.76 | -13.95 |
| Operating Cash Flow | -41.73 | -15.00 | -11.91 |
| Capital Expenditures | -2.00 | -2.15 | -1.30 |
| Free Cash Flow | -43.73 | -17.15 | -13.21 |
| Cash & Equivalents | 113 | 48.58 | 61.36 |
| Total Debt | 10.60 | 4.39 | 3.74 |
| Net Cash / Debt | 103 | 44.19 | 57.62 |
| Assets | 144 | 68.25 | 73.73 |
| Liabilities | 25.85 | 23.85 | 11.61 |
| Book Value | 118 | -60.38 | -42.66 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
HOOKIPA Pharma Inc. |
| Country |
United States |
| Employees |
85 |
| CEO |
Jörn Aldag |
Stock Information
| Ticker Symbol |
HOOK |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: HOOK |
| IPO Date |
April 18, 2019 |
Description
HOOKIPA Pharma, a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.